Latest news
Updated: Replimune scores win as FDA advisors back melanoma treatment, bucking staff concerns - Endpoints NewsEndpoints News · Fri, 31 Jul 2026 07:00:00 GMTReplimune’s twice-rejected melanoma drug prevails in FDA adcomm - Fierce BiotechFierce Biotech · Thu, 30 Jul 2026 07:00:00 GMTDuchenne Families Face a Three-Week Wait After FDA Advisers Rejected the Heart Therapy Evidence - Medical DailyMedical Daily · Thu, 30 Jul 2026 07:00:00 GMTFDA expert committee votes in favor of Replimune’s melanoma treatment - statnews.comstatnews.com · Thu, 30 Jul 2026 07:00:00 GMTFDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting - BioSpaceBioSpace · Wed, 29 Jul 2026 07:00:00 GMT